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1. Introduction 
Nanotechnology offers tremendous potential for use in biomedical applications, including 
imaging, disease diagnosis, and drug delivery. The development of nanosystems has 
improved the molecular understanding of many diseases and permitted the controlled 
nanoscale manipulation of materials (Couvreur & Vauthier, 2006). Nanomedical platforms 
offer many advantages as delivery, sensing, and image-enhancing agents. In recent years, 
many studies have focused on multifunctional nanomedical platforms that incorporate 
therapeutic and diagnostic agents with molecular targeting capabilities. Gregoriadis et al. 
first proposed liposomes as drug carriers in cancer chemotherapy in 1974 (Gregoria et al., 
1974). Today, drug delivery systems made of lipids or polymers frequently are exploited for 
the controlled delivery of therapeutic drugs in the body (Jain, 2005; Vasir et al., 2005).  
Nanosized particles for biomedical platforms can be made from a variety of materials, 
including lipids (liposomes, nanoemulsions, and solid-lipid nanoparticles), self-assembling 
amphiphilic molecules, nondegradable and degradable polymers, dendrimers, metals, and 
inorganic semiconductor nanocrystals. The selection of the platform material is determined 
by the desired diagnostic or therapeutic goal, payload type, material safety profile, and 
administration route. Among the various types of functional nanostructures, nanomedical 
platforms based on magnetic nanoparticles (MNPs) are of particular interest in biomedical 
applications. Most frequently, MNPs are constructed of superparamagnetic iron oxides 
(SPIOs) (e.g., Fe3O4 or γ-Fe2O3), although metals such as cobalt and nickel are also employed. 
The characteristics of MNPs, including their composition, size, morphology, and surface 
chemistry, are tailored by various processes for their wide application in the detection, 
diagnosis, and treatment of illnesses. The most popular MNPs for biomedical applications 
are comprised of a magnetic inorganic nanoparticle core and a biocompatible surface 
coating that provides stabilization under physiological conditions. The additional 
application of a suitable surface chemistry allows the integration of functional ligands, such 
that MNPs can perform multiple functions. The modification and functionalization of MNPs 
improve their magnetic properties and affect their behavior in vivo (Tartaj et al., 2003; A.K. 
Gupta & M. Gupta, 2005).  
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Multifunctional MNPs (MFMNPs) are a major class of nanoscale materials with the potential 
to revolutionize clinical diagnostic and therapeutic techniques. Due to their unique magnetic 
properties and ability to function at the cellular and molecular levels of biological 
interactions, MFMNPs have been investigated as an attractive nanomedical platform. 
MFMNPs in the form of SPIOs have been actively investigated as contrast enhancement 
agents for magnetic resonance imaging (MRI) and hyperthermia in response to an external 
alternating magnetic field, due to their ability to enhance the proton relaxation of specific 
tissues. MFMNPs have been evaluated extensively as a nanomedical platform for the 
targeted delivery of pharmaceuticals through magnetic drug targeting (Neuberger et al., 
2005) and through the attachment of high-affinity ligands (Zhang et al., 2002; Torchilin, 
2006). 
2. Surface coatings and functionalization of MNPs 
2.1 Core–shell structure 
Iron oxides with a core/shell structure are widely used as sources of MFMNP platforms. 
Iron oxides have several crystalline polymorphs, but only γ-Fe2O3 (maghemite) or Fe3O4 
(magnetite) can be used for biomedical applications. These particles, which range in 
diameter from about 5–20 nm, have unique advantages, including (1) superparamagnetic 
behavior, with no magnetism after removal of the magnetic field; (2) high saturation 
magnetization values and high magnetic susceptibility, for effective magnetic enrichment; 
(3) biocompatibility and rapid removal through extravasation and renal clearance; and (4) 
easily tailored surface chemistry and functionalization.  
Iron oxide nanoparticles have a significant tendency to agglomerate as a result of their high 
surface energy. Massart (1981) first prepared stable aqueous dispersions of Fe3O4 
nanoparticles (ferrofluids) that were stabilized by electrical double layers. However, the 
colloidal electrostatic stabilization arising from surface charge repulsion on the 
nanoparticles typically is inadequate to prevent aggregation in biological solutions, due to 
the presence of salts or other electrolytes that can neutralize the charges. Furthermore, the 
iron oxide surfaces may be subjected to plasma protein adsorption or opsonization, leading 
to their rapid clearance by the reticuloendothelial system (RES) (Berry & Curtis, 2003).  
To solve the above problems, proper surface coatings have been exploited as an integral 
component of the MFMNP platform for biomedical applications. The iron oxide core can be 
coated by organic materials [e.g., polymers such as dextrant (Thorek et al., 2006) and 
polyethylene glycol (PEG) (Gref et al., 1994)], inorganic metallic materials [e.g., gold (Ji et al., 
2007)], or oxides [e.g., silica or alumina (Bumb et al., 2008)].  Polymer coatings will be 
introduced in detail in the next section. Silica shells are attractive as protective coatings on 
the iron oxide core, due to their stability under aqueous conditions and ease of synthesis. 
Recently, Ma et al. (2006) described one such core–shell MFMNP, composed of an iron oxide 
core (approximately 10 nm diameter) surrounded by a SiO2 shell (10–15 nm thick). They 
doped an organic dye, tris(2,2′-bipyridine) ruthenium, inside a second silica shell to provide 
luminescence and prevent quenching by interaction with the magnetic core. As a core–shell 
structure exhibiting superparamagnetic and luminescent properties, this MFMNP platform 
can be used as a multifunctional imaging agent for biomedical applications.  
Gold offers several advantages as a coating material for iron oxide cores, due to its low 
chemical reactivity and unique ability to form self-assembled monolayers on the core 
surface using alkanethiols (Prime & Whitesides, 1991). A variety of methods (reversed 
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microemulsion, combined wet chemical, and laser irradiation) can be used to synthesize 
gold-coated iron oxides (A. H. Lu et al., 2007).  
The core/shell structure of MFMNPs offers several advantages, including good 
dispersibility and high stability against oxidation. In addition, an appreciable amount of 
therapeutic agent can be loaded on the MFMNP shell. Functionalization chemistries 
generally are better established when a coating material is used. 
2.2 Polymer coatings 
Polymers comprise some of the most important materials used as shells. Polymer coatings 
not only provide a steric barrier to prevent nanoparticle agglomeration, but also allow 
MNPs to evade uptake by the RES and thereby to maintain a long plasma half-life. Polymer 
coatings provide a means to tailor the surface properties of MNPs, such as the surface 
charge and chemical functionality. An ideal polymer coating will have a high affinity for the 
iron oxide core, as well as nonimmunogenic and nonantigenic properties. It also will 
prevent opsonization by plasma proteins. Polymer materials comprised of lipids, proteins, 
dendrimers, gelatin, dextran, chitosan, pullulan, PEG, poly(ethylene-co-vinyl acetate), 
poly(vinylpyrrolidone), poly(vinyl alcohol) (PVA), or poly(glycerol monoacrylate) (PGA) 
are often chosen as the surface coatings for MNPs.  
PEG is the most widely used polymer for nanoparticle coating in biomedical applications. 
PEG provides a very attractive combination of properties: excellent solubility in aqueous 
solutions; high flexibility of its polymer chain; very low toxicity, immunogenicity, and 
antigenicity; lack of accumulation in the RES cells; and minimal influence on the specific 
biological properties of modified pharmaceuticals (Yamaoka et al., 1994). As a so-called 
“stealth” surface, PEG prevents the nanomedical platform from being recognized by RES, 
and thereby extends its blood circulation time in vivo. On the biological level, coating 
nanoparticles with PEG sterically hinders the interaction of blood components with the 
nanoparticle surface and reduces the binding of plasma proteins. Mechanisms of 
preventing opsonization by PEG include the shielding of the surface charges, increased 
surface hydrophilicity (Gabizon & Papahadjopoulos, 1992), and enhanced repulsive 
interaction between polymer-coated nanoparticles and blood components (Needham et 
al., 1992). Various methods have been utilized to attach PEG to the MNP surface, 
including silane grafting to the oxide surface (Butterworth et al., 2001), alkaline 
coprecipitation of ferric and ferrous ions in the presence of PEG-containing block 
copolymers (Wan et al., 2005), direct attachment of PEG-containing block copolymers 
(Guo et al., 2010), polymerization at the MNP surface (Flesch et al., 2005), and 
modification through sol-gel approaches (Y. Lu et al., 2002). 
Polysaccharide dextran is another polymer coating that has been used widely and 
successfully in vivo. Dextran-coated iron oxide nanoparticles have become an important 
part of clinical cancer imaging, and have been shown to increase the accuracy of cancer 
nodal staging (Harisinghani & Weissleder, 2004; Ferrari, 2005). Because the dextran coating 
is not strongly associated with the iron oxide core, the polymer is susceptible to detachment. 
Accordingly, cross-linked iron oxide nanoparticles have been developed by cross-linking the 
dextran shell with epichlorohydrin (Josephson et al., 1999). The resulting particle offers 
superb stability under harsh conditions, without causing any change in size or blood half-
life or loss of the dextran coat. Chemical functionality can be established by treating cross-
linked iron oxide nanoparticles with ammonia to provide primary amino groups for the 
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attachment of biomolecules such as proteins or peptides (Wunderbaldinger et al., 2002; 
Schellenberger et al., 2002). These formulations of dextran-coated iron oxide nanoparticles 
have been evaluated extensively for a variety of MRI applications (Josephson et al., 1999).  
In addition to the traditional polymer coatings, a new kind of biocompatible polymer 
material has been reported by Wan et al. (2005): namely, homopolymers of glycerol 
monoacrylate or glycerol monomethacrylate, or their block copolymers. Highly stable 
aqueous magnetic fluids were prepared by coating Fe3O4 nanoparticles with poly(glycerol 
monoacrylate) (PGA), poly(glycerol monomethacrylate) (PGMA), or diblock copolymers 
with PGA or PGMA segments. As shown in Fig. 1, the proposed mechanism of stabilization 
was the multidentate interactions of 1,2-diols on the polymer chain with iron atoms at the 
surface of the iron oxide nanoparticles (Wan et al., 2005). This process was a good choice for 
the preparation of stable magnetic fluids with tailored surfaces; PGA or PGMA binds very 
tightly to the iron oxide surface, is highly hydrophilic, and does not introduce charges on 
the surface. Moreover, various block copolymers containing PGA or PGMA can be used to 
modify the iron oxides and to introduce tailored functional groups for further 
functionalization. 
 
 
Fig. 1. Proposed structure in the interaction between the iron oxide surface and PGA (Wan 
et al., 2005). 
2.3 Functional ligands 
As discussed in the above sections, the core–shell structure of MFMNPs provides a means to 
tailor the nanoparticle surface properties, such as surface charge and chemical functionality. 
Various functional ligands, including targeting agents, permeation enhancers, optical dyes, 
and therapeutic agents, can be conjugated on the surface or incorporated within the 
nanostructure. The modification of the nanoparticle surface with targeting ligands was 
described recently as a promising biotargeting strategy. To generate target-specific 
nanoparticles, various biological molecules, such as antibodies, proteins, small molecular 
targeting agents, etc., can be bound to the coating surfaces of the MFMNPs by chemical 
coupling. Tumor cells are rapidly proliferating and overexpress certain receptors that lead to 
the enhanced uptake of nutrients, including folic acid, vitamins, sugars, and proteins. 
MFMNPs conjugated with these molecules can be targeted to tumor cells that overexpress 
the corresponding receptors. Table 1 summarizes a number of different ligands and their 
corresponding functions that have been investigated for the in vivo targeting of MFMNPs. 
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Targeting ligand Functional activity References 
Folic acid 
Preferentially targets cancer cells that 
overexpress folate receptors and facilitates 
internalization
Zhang et al., 2002 
CREKA peptide 
or F3 peptide 
Targets an antigen associated with colorectal 
carcinoma cells
Reddy et al., 2006; 
Simberg et al., 2007 
Pullulan Increases receptor-mediated hepatic uptake Kaneo et al., 2001 
Elastin 
Cross-linked protein; Provides elasticity for 
many tissues
Debelle & Tamburro, 
1999
RGD peptide 
Enhances cell spreading, differentiation, and 
DNA synthesis
Bhadriraju & Hansen, 
2000
Tat-peptide 
Membrane-permeating peptide; Enhances 
intracellular delivery of nanoparticles
Josephson et al., 1999; 
Lewin et al., 2000 
Transferrin 
Targets primary proliferating cells by transferrin 
receptors
Weissleder et al., 2000; 
Moore et al., 2001 
Insulin Hormone; Regulates blood glucose levels Gupta et al., 2003 
Monoclonal 
antibody A7 
Targets an antigen associated with colorectal 
carcinoma cells
Toma et al., 2005 
Table 1. Selected functional ligands used for MFMNPs in biomedical applications 
Organic dyes or fluorophores have been loaded on MNPs as optical imaging agents to allow 
detection by multiple imaging modalities. In addition to their use as contrast enhancement 
agents, FITC- (Zhang et al., 2002), rhodamine- (Bertorelle et al., 2006), or other fluorophore-
labeled MNPs can be used for the in vitro fluorescent imaging of cells. Since both MRI and 
optical signals come from the same nanoparticles, the MR image can serve as a roadmap to 
the fluorescently labeled tumor cells. The conjugation of near-infrared fluorescent (NIRF) 
dyes to MNPs has received recent attention due to the deep penetration of NIRF light in the 
tissues (Weissleder & Ntziachristos, 2003). The integration of NIRF detectability allows for 
these nanoparticles to be used for presurgical planning by MRI and intraoperative resection 
of malignant tissues by optical imaging.  
3. Biomedical applications of MFMNPs 
3.1 Targeted drug delivery 
One promising biomedical application of MFMNPs is as carriers for site-specific drug 
delivery. Many therapeutic agents, while pharmacologically effective, also exhibit side-
effects because of their toxicities. For example, cytotoxic compounds used in cancer therapy 
kill not only target cells but also normal cells in the body, resulting in undesired side-effects. 
Meanwhile, many barriers to the delivery of therapeutic agents are presented, including 
renal clearance of small molecular therapeutic agents and overexpressed membrane-
associated multi-drug resistance developed by tumor cells. Therefore, many therapeutic 
agents are limited in their clinical application. As widely used nanocarriers, MFMNPs have 
been considered as alternatives for the target-specific delivery of drugs to different sites in 
the body. These engineered nanoparticulate carriers offer some advantages, including 
passive targeting due to the enhanced permeability and retention (EPR) effect and 
functionalized surface features for target-specific localization. It also may be possible to 
develop nanocarriers that respond to physiological stimuli, or to combine drugs with energy 
(heat, light, and sound) delivery for synergistic therapeutic effects. 
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3.1.1 Passive targeting 
Passive targeting relies on the properties of the delivery system and the disease pathology to 
accumulate the drug preferentially at the site of interest and avoid nonspecific distribution. 
Long-circulating nanoparticles of 20-200 nm in diameter containing surface PEG or 
poly(ethylene oxide) (PEO) blocks can accumulate at sites of disease such as tumors, 
infection, or inflammation through passive targeting via the EPR effect. Maeda and 
colleagues (2001) first described the EPR effect in their study of vascular abnormalities of 
solid tumors. Blood vessels in most solid tumors possess unique characteristics that are not 
usually observed in normal blood vessels, including: active angiogenesis and high vascular 
density; extensive production of vascular mediators that facilitate extravasation; defective 
vascular architecture (lack of smooth muscle layer cells, lack of receptors for angiotensin, 
large gap in endothelial cell-cell junctions, and anomalous conformations); and impaired 
lymphatic clearance of macromolecules and lipids from interstitial tissue.  
Due to the EPR effect, nanopharmaceuticals (macromolecular drugs and drug-loaded 
nanoparticles) accumulate in tumor tissues with remarkable selectivity as schematically 
illustrated in Fig. 2. For example, the administration of polymer-drug conjugates results in 
10-100 fold higher drug concentrations in the tumor compared to the administration of free 
drug (van Vlerken et al., 2007). This selective drug targeting to solid tumors results in 
substantial therapeutic benefits due to the higher drug accumulation in the tumor tissue, as 
well as fewer side effects. The EPR effect also has been observed in inflammatory and 
infectious tissues. Thus, the application of nanocarriers is expected to have therapeutic 
benefits for treating these diseases as well (Allen & Cullis, 2004).  
 
 
Fig. 2. Schematic illustration for passive targeting using the EPR effect. 
Another approach for passive targeting involves the tendency of nanoparticles to localize in 
the RES. This phenomenon provides an opportunity for nanoparticles to accumulate at high 
concentrations in the liver or spleen, where many macrophages are present. Overall, the 
passive targeting strategy provides a means of delivering MFMNPs (as contrast agents or 
drug carriers) or other nanoparticles to the targeted organs or tissues. 
3.1.2 Active targeting 
Another promising approach towards increasing the local accumulation of nanoparticles in 
diseased tissue is known as active (or specific) targeting. Active targeting involves the 
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conjugation of targeting molecules that possess high affinity toward unique molecular 
signatures found on malignant cells. Targeting ligands, such as proteins, peptides, aptamers 
and small molecules, have been investigated to increase the site-specific accumulation of 
MFMNPs. For example, there are certain receptors that are overexpressed on the surface of 
solid tumor cells, such as antigens, integrin receptors, and folate receptors (Table 1). By 
bonding with these targeting molecules, MFMNPs can be targeted to the corresponding 
tumor cells and internalized by receptor- or antigen-mediated endocytosis.  
Monoclonal antibodies (mAbs) were the first targeting agents to exploit molecular 
recognition to deliver MNPs; mAbs continue to be used widely, due to their high specificity. 
For instance, Herceptin®, an FDA-approved mAb to the HER2/neu (erbB2) receptor, has 
been used to modify DMSA-coated magnetite nanoparticles. When these MFMNPs were 
used as contrast enhancement agents, the MR imaging of mice bearing xenograft tumors 
showed a T2 decrease of ~20% due to the specific accumulation of the nanoprobe in the 
tumor (Huh et al., 2005). Nanoparticles modified with an HER2-specific antibody 
(Trastuzumab® or Herceptin®) also are able to localize and deliver the therapeutic payload 
specifically in HER2-expressing tumor cells (Kirpotin et al., 2006). Certain tumor cells 
express specific integrin receptors, such as ǂvǃ5 or ǂvǃ3 that can bind to the arginine-glycine-
aspartic acid (RGD) peptide sequence. The RGD peptide has been utilized for the delivery of 
MNPs to a variety of neoplastic tissues, including breast tumors, malignant melanomas, and 
squamous cell carcinomas (Montet et al., 2006). 
Among the small targeting molecules, folate has been used to modify nanoparticles for 
targeted delivery to tumor cells that overexpress folate receptors. Recently, our group 
reported multilayer MFMNPs with a folate-modified surface and doxorubicin (an anticancer 
chemotherapeutic agent) loaded in the inner shell (Fig. 3) (Guo et al., 2011). The folate-
conjugated MFMNPs displayed a much greater cellular uptake than nonfolate-conjugated 
MFMNPs by a folate receptor–mediated endocytosis process (Fig. 4). Folate conjugation 
significantly increased nanoparticle cytotoxicity against human cervical carcinoma HeLa 
cells (Guo et al., 2011).  
 
 
Fig. 3. Schematic illustration of multilayer MFMNPs with folate as the targeting ligand and 
loaded doxorubicin as the anticancer chemotherapeutic agent in the inner shell. 
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Fig. 4. Confocal microscopic images of HeLa cells incubated with (a, b) doxorubicin-loaded 
MFMNPs without folate conjugation or (c, d) folate–conjugated and doxorubicin-loaded 
MFMNPs in (a, c) folate-containing or (b, d) folate-free media (Guo et al., 2011). 
3.1.3 Drug loading and controlled release 
An essential step in the use of MFMNPs for drug delivery is the controlled release of the 
therapeutic payload in the desired tumor cells or tissues. The drug-loading capacity and 
release rate are correlated with the binding affinity of the drug. Strong carrier–drug 
interactions may enhance the loading capacity and decrease the release rate of the drug from 
the carrier; therefore, the choice of proper carrier–drug interactions is critical in the design 
and preparation of nanocarriers for drug delivery. 
Successful MNP delivery devices with a prolonged circulation time can carry a 
chemotherapeutic payload and can be engineered to release its drugs after cell 
internalization. To successfully integrate a drug into a NP system, several design strategies 
can be explored, including physical complexation with hydrophobic drugs, or covalent 
bonding with cleavable linkages for intracellular release. Currently, several chemical drug 
formulations have been combined with MNPs, including paclitaxel, doxorubicin, and 
methotrexate, all specifically developed for cancer therapy. For example, methotrexate, an 
anticancer drug, has an affinity to the target cells, and after grafting the drug to the surface, 
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MNPs can be internalized more rapidly. Kohler et al. (2006) first demonstrated this utility in 
a study where methotrexate was covalently attached to the surface of PEG-coated MNPs via 
a cleavable amide linkage. Recently, Sun et al. (2008b) further modified the same MFMNP 
system with chlorotoxin to enhance the NP's targeting abilities against brain tumor cells. 
Ideal drug delivery systems should be stable with a long circulation time, and should keep 
the loaded drugs unreleased during circulation in the bloodstream or in normal tissues. 
Upon reaching the tumor tissues and being taken up by cancer cells, the systems should 
release the drugs rapidly to kill cancer cells.  
To achieve this purpose, stimuli-triggered drug delivery systems have been used that 
respond to characteristics of the local microenvironment, such as pH, temperature, redox 
potential, etc. [reviewed by Danhier et al. (2010) and Muthu et al. (2009)]. In particular, pH 
gradients have been used widely to design responsive nanoparticle delivery systems. 
Various nanocarriers with pH-responsive delivery behaviors have been developed on the 
basis of the differential pH values of blood plasma (pH 7.4), extracellular tumor matrix (pH 
5.8–7.2), and endocytic compartments such as endosomes (pH 5–6) and lysosomes (pH 4–5). 
Drugs have been loaded into polymeric nanocarriers by acidic pH-induced cleavable 
covalent bonds, creating smart drug delivery systems that respond to the 
endosomal/lysosomal pH (Yoo et al., 2002; Bae et al., 2003; Gillies et al., 2004; Hruby et al., 
2005). The pH-induced cleavage of such bonds can accelerate drug release from the 
nanocarriers. 
Drugs are otherwise loaded into the core of polymeric micelles by noncovalent (e.g., 
hydrophobic) interactions. Compared to chemical attachment, noncovalent entrapment is 
convenient and easy to achieve. Nasongkla et al. (2006) described the preparation of micelles 
of PEG-b-poly(D, L-lactide) that encapsulated doxorubicin and a cluster of SPIO 
nanoparticles by noncovalent hydrophobic interactions. The protonation of doxorubicin 
under acidic conditions increased its water-solubility and induced its release.  
Recently, our group reported a MFMNP platform that can load drugs with ionizable groups 
and hydrophobic moieties by the combined action of ionic bonding and hydrophobic 
interactions (Guo et al., 2008, 2010) (Fig. 5). The use of double noncovalent interactions 
resulted in a high loading affinity at a neutral pH (7.4), preventing premature release into 
the bloodstream. At an endosomal/lysosomal pH (<5.5), protonation of polycarboxylate 
anions in the polymer chains led to ionic bond breakage and drug release. The release 
process was controlled, responded well to pH, and displayed good kinetics. 
 
 
Fig. 5. Schematic illustration of the MFMNP structure, and the load and release of model 
drug adriamycin (ADR) (Guo et al., 2008). 
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3.2 MRI 
MRI is a powerful noninvasive imaging modality that is utilized widely in clinical medicine. 
MRI is based on the property that hydrogen protons will align and process around an 
external alternating magnetic field. The subsequent process through which these protons 
return to their original state is referred to as the relaxation phenomenon. Two independent 
processes, longitudinal relaxation (T1-recovery) and transverse relaxation (T2-decay), are 
monitored to generate the MR image. Local variations in relaxation, corresponding to image 
contrast, arise from the proton density and the chemical and physical natures of the 
different tissues. Due to their ability to enhance proton relaxation and accumulation in 
specific tissues, MFMNPs have been actively investigated as contrast enhancement agents 
for MRI. 
3.2.1 Magnetic properties of iron oxide nanoparticles 
Particles whose unpaired electron spins align themselves spontaneously so that the material 
can exhibit magnetization without being in a magnetic field are called ferromagnetic 
particles. Materials such as iron oxide nanoparticles that exhibit ferromagnetism can be 
permanently magnetized. The magnetic properties of iron oxide nanoparticles can be 
described by the dependence of the magnetic induction B on the magnetic field H. For most 
materials, the relationship between B and H is linear: B = µH, where µ is the magnetic 
permeability of the particles. Iron oxide particles exhibit paramagnetism if µ > 1, and 
diamagnetism if µ < 1.  
Usually, ferromagnetic properties arise only when a certain number of atoms are bound 
together in solid form; single atoms cannot exhibit ferromagnetism. When the size of particles 
is smaller than the ferromagnetic domain, they are no longer ferromagnetic but exhibit 
superparamagnetism (Bansil et al., 1998). Magnetic nanoparticles smaller than ~ 30 nm show 
superparamagnetic behavior without any magnetic remanence (i.e., restoration of the induced 
magnetization to zero upon removal of the external magnetic field), but the particles still 
exhibit very strong paramagnetic properties with a very large susceptibility. This is one 
important advantage for magnetic nanoparticles: it enables their stability and dispersion upon 
removal of the magnetic field, as no residual magnetic force exists between the particles.  
In MRI, superparamagnetic nanoparticles made of iron oxide act as contrast enhancement 
agents by shortening both the T1 and T2 relaxations of the surrounding protons. The 
influence on the T1 relaxation depends strongly on the local MNP concentration, and the 
shortening processes can be hindered by the coating thickness. The effect of MNPs on T2 
shortening is caused by the large susceptibility difference between the particles and 
surrounding medium, which results in microscopic magnetic field gradients. At low 
concentrations, a T1-positive contrast can be observed; at high concentrations, the 
susceptibility effects cause irreversible destruction of the MR signal around the particles.  
NMP agglomeration tends to slightly decrease the T1 relaxation times but markedly 
decrease the T2 times. Therefore, superparamagnetic nanoparticles typically are used to 
provide negative contrast enhancement using T2-weighted pulse sequences. The 
effectiveness of a contrast agent can be described by its relaxivity, which is the 
proportionality constant of the measured rate of relaxation, or R1 (1/T1) and R2 (1/T2). The 
relaxivity depends on not only the composition, size, and magnetic properties of the MNP, 
but also depends on experimental variables such as the field strength, temperature, and 
medium in which the measurements are made. 
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3.2.2 Molecular imaging in cancer 
The generation of new molecular targets that are closely related to pathophysiology will 
open the way for the development of new treatment paradigms for currently untreatable 
diseases. In recent years, many new diagnostic technologies have been developed, including 
molecular diagnostic compounds and new imaging technologies such as MR molecular 
imaging. Molecular imaging is the noninvasive imaging of targeted macromolecules, cells, 
and biological or cellular processes in living organisms. Due to their ability to act as 
molecularly targeted imaging agents, MNPs play an integral role in the applications of early 
disease detection, individualized treatment, and drug development. In the clinical imaging 
of tumors, MNPs can be used as contrast enhancement agents to improve the detection, 
diagnosis, and therapeutic management of solid tumors by exploiting the unique molecular 
signatures of the diseases. MNPs also have been investigated to improve the delineation of 
the tumor position, boundaries, and volume. 
The first clinical indication for iron oxide nanoparticles was the imaging of liver tumors and 
metastases. After intravenous injection, MNPs are taken up rapidly by hepatic specialized 
macrophages. This process causes a drop in MR signal intensity and generates hypointense 
images, mostly because of a susceptibility effect. However, tumors lack a permanent 
decrease in signal intensity after MNP administration; tumors are almost devoid of 
macrophages, which are located exclusively in the healthy hepatic parenchyma. Therefore, 
MNPs can markedly increase the contrast between healthy and diseased tissue. The clinical 
imaging of liver tumors and metastases through RES-mediated uptake of MNPs has allowed 
the detection of lesions as small as 2–3 mm (Semelka & Helmberger, 2001). In combination 
with MRI, MNPs also have been shown to be effective in the identification of lymph node 
metastases of 5–10 mm in diameter (Harisinghani et al., 2003). The use of MFMNPs as 
contrast enhancement agents provides increased lesion conspicuousness and lesion 
detection compared to nonenhanced imaging.  
MFMNPs are currently under evaluation for use in improving the delineation of brain 
tumor boundaries and quantifying tumor volumes (Enochs et al., 1999; Neuwelt et al., 2004). 
Some recent approaches have explored utilizing iron oxide nanoparticles as drug delivery 
vehicles for the MRI-monitored magnetic targeting of brain tumors (Chertok et al., 2008). 
The accumulation of iron oxide nanoparticles in gliosarcomas is enhanced by magnetic 
targeting and successfully quantified by MRI (Chertok et al., 2008) (Fig. 6). Such noninvasive 
approaches for cancer diagnosis and therapy also have been adopted in the treatment of 
prostate, breast, and colon cancers. 
As both drug delivery devices and MRI contrast enhancement agents, MNPs retain the ability 
to track the movement of drug through the body. This is significant because it allow clinicians 
to monitor the effectivity of injected therapeutics to reach their target sites. There remains 
significant flexibility in the contrast agents implemented in these constructs and the manner in 
which drugs are delivered. Medarova et al. (2007) recently developed cross-linked iron oxide 
nanoparticles modified with a NIR fluorophore, therapeutic siRNA sequences, and a cell 
penetrating peptide. The MNPs used passive targeting by the EPR effect to direct tumor 
localization. In vivo, these MNPs demonstrated therapeutic efficacy against target tissue, as 
determined by real time PCR and histological evaluation, while simultaneously demonstrating 
image contrast in both MR and optical imaging. In a study by Sun et al. (2008a) active cell 
targeting was shown by PEG-coated MNPs to which the chemotherapeutic, methotrexate, and 
targeting molecule, chlorotoxin, were attached. The selective contrast enhancement of the 9L 
brain tumor by these MNPs indicates preferential accumulation compared with the same 
MNP construct without the chlorotoxin peptide in a 3-day study. 
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Fig. 6. MR images of brain tumor. Change in the R2 relaxation for the tumor regions before 
(baseline) and 1–3 h after MNPs administration in (A) control and (B) targeted rats  
(Chertok et al., 2008). 
In another recent study by Yang et al. (2007) simultaneous targeted drug delivery and MR 
imaging of breast cancer tumors were demonstrated through the use multifunctional 
magneto-polymeric nanohybrids composed of magnetic nanocrystals and doxorubicin 
which were simultaneously encapsulated within an amphiphilic block copolymer shell. The 
surfaces of these micelles were additionally functionalized with the breast cancer 
targeting/therapeutic ligand, anti-Herceptin antibody. In vivo evaluations of this 
nanoparticle system were performed in nude mice bearing NIH3T6.7 breast cancer tumors. 
The quantitative evaluation of MR images revealed preferential accumulation of the 
targeted MNPs compared to the control MNPs. The therapeutic functionality of the MNPs 
developed in this study were additionally evaluated and it was determined that the HER-
MMPNs which were decorated with targeting ligands and loaded with doxorubicin were 
most effective in inhibiting tumor growth. Combined, these findings illustrate the 
functionality and efficacy of targeted multifunctional MNPs for simultaneous MR imaging 
and drug delivery. 
3.3 Hyperthermia 
Hyperthermia is the method of using heat as a treatment for malignant tumors. It is based 
on the observation that tumor cells are more susceptible to heat than normal cells, due to the 
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higher rates of metabolism of cancer cells. Cancer cells typically show signs of apoptosis and 
necrosis when heated to 41-47 °C, whereas normal cells can survive at higher temperatures 
(Milleron & Bratton, 2007). Hyperthermia with targeted nanoscale heaters is recognized as a 
useful therapeutic modality to kill cancer by essentially “cooking” malignant cells from the 
inside out.  
Magnetic nanoparticle hyperthermia is actualized by the exposure of cancer tissues to an 
alternating magnetic field. The magnetic field cannot be absorbed by the living tissues 
and can be applied to deep regions in the living body. When MNPs are injected into an 
organ with a tumor, they tend to accumulate in the tumor due to passive and active 
targeting strategies (as described above). Subsequent exposure to an alternating magnetic 
field causes heat to be generated in the tumor tissue due to magnetic hysteresis loss. This 
process effectively destroys the tumor but not the surrounding healthy tissue. The amount 
of heat generated depends on the nature of the MNPs and magnetic field parameters 
used. 
The use of MFMNPs for targeted hyperthermia has shown a therapeutic effect in several 
types of tumors. Using dextran-coated MNPs conjugated to breast cancer–targeting chimeric 
L6 mAb, DeNardo et al. (2005) demonstrated the feasibility of this method for treating breast 
cancer cells. Kobayashi et al. constructed a novel therapeutic tool of magnetite nanoparticle-
loaded anti-HER2 immunoliposomes that was applicable to the treatment of HER2-
overexpressing cancer (Ito et al., 2004).  
A clinical breakthrough in MNP use was made in 2007, when Maier-Hauff et al. (2007) 
reported the results of using heated implanted MNPs for therapeutic hyperthermia in 
humans. In that study, 14 patients with recurrent glioblastoma multiforme, a type of severe 
brain cancer, received an intratumoral injection of aminosilane-coated MNPs. The tumor 
sites were located by several comprehensive MRI scans, and the patients were exposed to an 
alternating magnetic field to induce particle heating. The nanoparticle deposits were stable 
for several weeks, and all patients tolerated the nanoparticles without any complications. 
These findings indicate that MNP hyperthermia may be an effective therapeutic method to 
cure human brain cancer.  
As a potential approach for the treatment of malignant tumors, MNP hyperthermia has the 
following advantages: it provides a noninvasive way to raise cell temperatures to a 
therapeutic level; MNPs can be visualized using MRI, thus combining diagnostic and 
therapeutic approaches in one type of particle; and the particles can be functionalized and 
combined with other types of treatment, such as chemotherapy or radiotherapy. 
4. Conclusions 
Multifunctional nanomaterials have been widely used as nanoplatforms for multimodal 
imaging or simultaneous imaging and therapy. As a multifunctional nanoplatform with 
many biomedical applications, MFMNPs of various formulations have been developed to 
diagnose and treat diseases for which conventional therapy has shown limited efficacy, such 
as cancer. The use of MFMNPs as MRI contrast enhancement agents and anticancer drug 
carriers has drawn enormous attention, and may provide new opportunities for early cancer 
detection and targeted therapies. This technology not only will minimize the need for 
invasive procedures, but also will reduce the side effects to healthy tissues, which are 
primary concerns in conventional cancer therapies. 
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